Treats heartburn and other symptoms associated GERD. ANDA 206055, held by Zydus Pharms. Esomeprazole Magnesium.
As of Nov 16, 2026, ANDA 206055 (Esomeprazole Magnesium), held by Zydus Pharms, was first approved by FDA on Jun 7, 2023, with 1 approved supplement and 0 published complete response letters.
Esomeprazole magnesium for delayed-release oral suspension is a proton pump inhibitor (PPI). Esomeprazole magnesium for delayed-release oral suspension are indicated for the: Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 12 years to 17 years of age. Maintenance of healing of EE in adults. Short-term treatment of heartburn and other symptoms associated GERD in adults and pediatric patients 12 years to 17 years of age. Risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 7, 2023 | Original application | Approved | None posted |
| Esomeprazole MagnesiumEQ 20MG BASE/PACKET · for suspension, delayed release;oral | Esomeprazole Magnesium | Rx |
| Esomeprazole MagnesiumEQ 40MG BASE/PACKET · for suspension, delayed release;oral | Esomeprazole Magnesium | Rx |
| Nov 8, 2023 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jun 7, 2023 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters